Glymphatic system impairment contributes to the formation of brain edema after ischemic stroke

Abstract

The blood-brain barrier (BBB) damage has traditionally been considered to determine the occurrence and development of post-stroke brain edema, a devastating and life-threatening complication. However, no treatment strategy targeting BBB damage has been proven clinically effective in ameliorating brain edema. Here, we found that the extravasation of protein-rich fluids into the brain was not temporally correlated with edema formation after middle cerebral artery occlusion (MCAO) in mice, as brain edema reabsorption preceded BBB closure. Strikingly, the time course of edema progression matched well with the glymphatic system (GS) dysfunction after MCAO. Pharmacological enhancement of the GS function significantly alleviated brain edema developed on day 2 after MCAO, accompanied by less deposition of Aβ and better cognitive function. Conversely, functional suppression of the GS delayed the absorption of brain edema on day 7 after MCAO. Moreover, patients with ischemic stroke revealed a consistent trend of GS dysfunction after reperfusion as MCAO mice, which was correlated with the severity of brain edema and functional outcomes. Collectively, these findings indicate that the GS is a key contributor to the formation of brain edema after ischemic stroke, and targeting the GS may be a promising strategy for the treatment of brain edema in ischemic stroke.

One Sentence Summary The function of the glymphatic system is a key factor in determining the formation or resolution of brain edema after ischemic stroke

• Download figure
• Open in new tab

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the National Natural Science Foundation of China (No. 81871030, 82072133, 82171345), the President Foundation of Nanfang Hospital, Southern Medical University (2021B017), Guangzhou Science and Technology Plan Project (202206010032), the Guangdong Basic and Applied Basic Research Foundation (2021A1515010922, 2021A1515011017)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study of stroke patients was performed following the Declaration of Helsinki and was approved by the Medical Ethics Committee of Nanfang Hospital (NO. NFEC-2019-189).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes